D. Fisher

J. Gribben, D. Neuberg, A. Freedman, 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.

J. Ritz, D. Zahrieh, D. Fisher, 2004, Blood.

A Multicenter, Phase II Study of Ibrutinib Plus FCR (iFCR) As Frontline Therapy for Younger CLL Patients

A. LaCasce, M. Davids, D. Fisher, 2017 .

Treatment of favorable, limited-stage Hodgkin's lymphoma with chemotherapy without consolidation by radiation therapy.

A. LaCasce, D. Fisher, J. Abramson, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I trial of parathyroid hormone to facilitate stem cell mobilization.

M. Konopleva, B. Yeap, E. Shpall, 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma.

A. LaCasce, A. Freedman, P. Armand, 2020, Blood advances.

Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study.

M. Davids, D. Fisher, E. Jacobsen, 2019, The Lancet. Haematology.

A phase 2 study of Rituximab‐Bendamustine and Rituximab‐Cytarabine for transplant‐eligible patients with mantle cell lymphoma

A. LaCasce, M. Faham, L. Weng, 2016, British journal of haematology.

TH2 Cytokines from Malignant Cells Suppress TH1 Responses and Enforce a Global TH2 Bias in Leukemic Cutaneous T-cell Lymphoma

R. Clark, R. Watanabe, E. Guenova, 2013, Clinical Cancer Research.

Prevalence of familial malignancy in a prospectively screened cohort of patients with lymphoproliferative disorders

A. LaCasce, D. Neuberg, A. Freedman, 2008, British journal of haematology.

Preexposure of resting B cells to interferon-gamma enhances their proliferative response to subsequent activation signals.

A. Freedman, J. Griffin, D. Fisher, 1987, Cellular immunology.

inducible gene expression, without significant toxicity - β / α interferon- rituximab in patients with non-Hodgkin lymphoma: increased Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and

J. Friedberg, R. Coffman, A. Freedman, 2013 .

Phase II study of a TLR‐9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma

Derick R. Peterson, J. Friedberg, R. Fisher, 2009, British journal of haematology.

Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity.

J. Friedberg, R. Coffman, A. Freedman, 2005, Blood.

Cyclophosphamide, Doxorubicin, Vincristine, Prednisone Dose Intensification With Granulocyte Colony-Stimulating Factor Markedly Depletes Stem Cell Reserve for Autologous Bone Marrow Transplantation

J. Gribben, D. Neuberg, J. Ritz, 1997 .

Radiotherapy Eradicates Malignant T Cells and Is Associated with Improved Survival in Early-Stage Mycosis Fungoides

R. Clark, P. Devlin, D. Fisher, 2019, Clinical Cancer Research.

Title: Radiation therapy eradicates malignant T cells and is associated with improved survival in early- stage mycosis fungoides Short title for running head: Radiation depletes skin malignant T cells in CTCL

A. Giobbie-Hurder, R. Clark, P. Devlin, 2019 .

Inpatient Considerations in the Diagnosis and Management of the Cutaneous T-Cell Lymphoma Patient

D. Fisher, N. LeBoeuf, Marianne C. Tawa, 2022, Current Dermatology Reports.

Alemtuzumab therapy for leukemic cutaneous T-cell lymphoma: diffuse erythema as a positive predictor of complete remission.

R. Clark, R. Watanabe, D. Fisher, 2014, JAMA dermatology.

Safety and Immunogenicity of Modi ﬁ ed Vaccinia Ankara in Hematopoietic Stem Cell Transplant Recipients: A Randomized, Controlled Trial

D. Fisher, M. Seaman, K. Verrill, 2013 .

Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity.

L. Rassenti, T. Kipps, J. Ritz, 2016, Blood.

The B Cell-Restricted Glycoprotein (B2) Is the Receptor for Epstein-Barr Virus

D. Fisher, A. Boyd, L. Nadler, 1986 .

Immunologic heterogeneity of diffuse large cell lymphoma.

G. Pinkus, A. Freedman, D. Fisher, 1985, Blood.

Clinical features and treatment outcomes for primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder: a retrospective cohort study from the Dana-Farber Cancer Institute and updated literature review

D. Fisher, T. Kupper, N. LeBoeuf, 2022, Leukemia & lymphoma.

Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician’s choice in cutaneous T-cell lymphoma: final data

M. Weichenthal, R. Dummer, O. Akilov, 2021, Blood advances.

Treatment of Refractory Cutaneous T-Cell Lymphoma: A Case History

D. Fisher, Marianne C. Tawa, 2011 .

Oral fludarabine has significant activity in patients with previously untreated chronic lymphocytic leukemia, and leads to increased STAT1 levels in vivo.

J. Gribben, J. Friedberg, D. Neuberg, 2004, Leukemia research.

Hairy cell leukemia: a tumor of pre-plasma cells.

D. Fisher, A. Boyd, L. Nadler, 1985, Blood.

Changes with in vitro Activation of the B Cell Panel Antigens

A. Freedman, D. Fisher, A. Boyd, 1986 .

Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk Lymphoma.

P. Armand, D. Fisher, R. Soiffer, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Poor outcome of CHOEP induction followed by gemcitabine/busulfan/melphalan high-dose therapy and stem cell rescue for patients with newly diagnosed peripheral T-cell lymphoma

E. D. Jacobsen, P. Armand, D. Fisher, 2022, Bone Marrow Transplantation.

Autologous Stem Cell Transplantation in Elderly Lymphoma Patients in Their 70s: Outcomes and Analysis.

A. LaCasce, P. Armand, D. Fisher, 2018, The oncologist.

Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia.

J. Gribben, J. Ritz, D. Fisher, 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Studies of in vitro activation and differentiation of human B lymphocytes. I. Phenotypic and functional characterization of the B cell population responding to anti-Ig antibody.

A. Freedman, D. Fisher, A. Boyd, 1985, Journal of immunology.

Hairy cell leukemia: a tumor of pre-plasma cells

D. Fisher, A. Boyd, L. Nadler, 1985 .

Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma.

A. LaCasce, D. Neuberg, B. Ebert, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Studies of the in vitro activation and differentiation of human B lymphocytes. II. Optimization of activation by anti-immunoglobulin antibody bound to beads: analysis of the role of autocrine effects on B-cell proliferation and of T-cell help in B-cell differentiation.

A. Freedman, D. Fisher, A. Boyd, 1986, Cellular immunology.

Predictive factors for radiation pneumonitis in Hodgkin lymphoma patients receiving combined-modality therapy.

A. LaCasce, A. Ng, B. Silver, 2012, International journal of radiation oncology, biology, physics.

Phase II Study of Dasatinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

A. LaCasce, D. Neuberg, P. Armand, 2011, Clinical Cancer Research.

Lyme meningoradiculitis and myositis after allogeneic hematopoietic stem cell transplantation.

U. de Girolami, D. Fisher, S. Chou, 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

CD 6-Depleted Allogeneic Bone Marrow Transplantation for Acute Leukemia in First Complete Remission

D. Fairclough, J. Ritz, A. Freedman, 1997 .

Prospective study of the efficacy of breast magnetic resonance imaging and mammographic screening in survivors of Hodgkin lymphoma.

R. Birdwell, D. Neuberg, A. Ng, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic value of minimal residual disease among patients with classical Hodgkin lymphoma undergoing autologous stem cell transplantation

A. LaCasce, P. Armand, D. Fisher, 2021, Leukemia & lymphoma.

Myocardial infarction in rheumatoid arthritis: The effects of DMARDs and prednisolone

C. Cooper, N. Arden, D. Fisher, 2008 .

Thyroid lymphoma on a background of Hashimoto's thyroiditis: PET/CT appearances.

A. Shinagare, S. Tirumani, D. Fisher, 2014, Clinical imaging.

Central nervous system lymphoma not detectable on single-photon emission CT with thallium 201.

D. Fisher, D. Burns, J. Fleckenstein, 1996, AJNR. American journal of neuroradiology.

Topical tofacitinib for the management of lymphocytic‐variant hypereosinophilic syndrome with cutaneous involvement

D. Fisher, T. Kupper, J. Merola, 2022, Dermatologic therapy.

Phenotypic Changes Occurring during in vitro Activation of Human Splenic B Lymphocytes

A. Freedman, D. Fisher, A. Boyd, 1986 .

Successful treatment of perianal giant condyloma acuminatum in an immunocompromised host with systemic interleukin 2 and topical cidofovir.

D. Fisher, R. Bleday, V. Nambudiri, 2013, JAMA dermatology.

Structural and functional characterization of IL 2 receptors on activated human B cells.

D. Fisher, A. Boyd, L. Nadler, 1985, Journal of immunology.

Comparison of MOPP versus ABVD as salvage therapy in patients who relapse after radiation therapy alone for Hodgkin's disease.

D. Neuberg, A. Ng, B. Silver, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Results of a prospective trial of mantle irradiation alone for selected patients with early-stage Hodgkin's disease.

A. Ng, B. Silver, N. Tarbell, 2001, Journal of Clinical Oncology.

Results o f a P rospective T rial o f M antle I rradiation A lone for S elected P atients W ith E arly-Stage H odgkin's D isease

A. Ng, B. Silver, N. Tarbell, 2001 .

Medical Management of Hemodynamically Unstable Sinoatrial Node Dysfunction in a Patient With Intracardiac Lymphoma

D. Fisher, A. Nohria, Colin A. Martz, 2021, JACC. CardioOncology.

A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients

S. Tyekucheva, P. Armand, M. Davids, 2020, Leukemia.

Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial.

A. Alencar, A. LaCasce, S. Tyekucheva, 2019, The Lancet. Haematology.

Phase 1 study of lenalidomide, bendamustine, and rituximab in previously untreated patients with chronic lymphocytic leukemia

D. Neuberg, P. Armand, M. Davids, 2019, Leukemia & lymphoma.

Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia.

L. Rassenti, T. Kipps, A. Freedman, 2019, Blood advances.

Ofatumumab plus high dose methylprednisolone followed by ofatumumab plus alemtuzumab to achieve maximal cytoreduction prior to allogeneic transplantation for 17p deleted or TP53 mutated chronic lymphocytic leukemia*

A. LaCasce, S. Fernandes, M. Davids, 2018, Leukemia & lymphoma.

Recovery after stem-cell transplantation for hematologic diseases.

D. Fairclough, Shaun Parsons, J. Weeks, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Routine screening for psychosocial distress following hematopoietic stem cell transplantation

P. Richardson, D. Fisher, R. Soiffer, 2005, Bone Marrow Transplantation.

Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

M. Weichenthal, R. Dummer, O. Akilov, 2017, The Lancet.

A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides/Sezary syndrome.

E. D. Jacobsen, P. Armand, D. Fisher, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Neurological Complications of Chemotherapy in Lymphoma and Leukemia Patients

P. Wen, D. Fisher, E. Quant, 2012 .

Obatoclax in combination with fludarabine and rituximab is well-tolerated and shows promising clinical activity in relapsed chronic lymphocytic leukemia

D. Neuberg, A. Freedman, D. Fisher, 2015, Leukemia & lymphoma.

A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma

A. LaCasce, D. Neuberg, L. Rassenti, 2013, Haematologica.

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Donna Neuberg, Steven M Kornblau, Johannes Köster, 2016, Cancer cell.

Immune reconstitution following high-dose chemotherapy and autologous stem cell transplantation with and without pembrolizumab maintenance therapy in patients with lymphoma.

A. LaCasce, J. Ritz, P. Armand, 2021, Transplantation and cellular therapy.

Human B Cell Populations Defined by the B1 and B2 Antigens

D. Fisher, A. Boyd, L. Nadler, 1986 .

Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma.

C. Rudin, R. Bourgon, Grégoire Pau, 2015, Cancer cell.

Genomic Analysis of Smoo thened Inhibitor Resistance in Basal Cell Carcinoma Graphical

C. Rudin, R. Bourgon, Grégoire Pau, 2015 .

Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non‐Hodgkin's lymphoma

J. Gribben, J. Friedberg, D. Neuberg, 2002, British journal of haematology.

Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma.

A. LaCasce, T. Batchelor, A. Muzikansky, 2012, Biology of Blood and Marrow Transplantation.

Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma

A. LaCasce, D. Neuberg, A. Freedman, 2013, Haematologica.

Circulating Th17 T cells at treatment onset predict autoimmune toxicity of PI3Kδ inhibitors

S. Tyekucheva, S. Rodig, S. Fernandes, 2023, Blood Cancer Journal.

Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission.

J. Gribben, D. Neuberg, A. Freedman, 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Molecular ontogeny of donor-derived follicular lymphomas occurring after hematopoietic cell transplantation.

D. Neuberg, J. Kutok, T. Sullivan, 2012, Cancer discovery.

CD20-Directed Antibody-Mediated Immunotherapy Induces Responses and Facilitates Hematologic Recovery in Patients With Waldenstrom’s Macroglobulinemia

J. Byrd, E. Kimby, D. Agus, 2001, Journal of immunotherapy.

Symptomatic extranodal Rosai-Dorfman disease treated with steroids, radiation, and surgery.

J. Jagannathan, D. Fisher, J. Hornick, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas

J. Friedberg, R. Fisher, D. Neuberg, 2009, British journal of haematology.

Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia.

J. Gribben, D. Neuberg, L. Sequist, 2005, Blood.

Autologous Bone Marrow Transplantation for Marginal Zone Non-Hodgkin's Lymphoma

J. Gribben, J. Friedberg, D. Neuberg, 2004, Leukemia & lymphoma.

Partial CD8+ T-cell depletion of allogeneic peripheral blood stem cell transplantation is insufficient to prevent graft-versus-host disease

D. Fisher, R. Soiffer, E. Milford, 2004, Bone Marrow Transplantation.

Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation.

D. Miklos, D. Fisher, R. Soiffer, 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Comparable outcome with T-cell-depleted unrelated-donor versus related-donor allogeneic bone marrow transplantation.

J. Gribben, J. Friedberg, A. Freedman, 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

in First Complete Remission CD6-Depleted Allogeneic Bone Marrow Transplantation for Acute Leukemia

D. Fairclough, D. Fisher, R. Soiffer, 2013 .

Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study.

A. LaCasce, S. Tyekucheva, M. Davids, 2021, The Lancet. Oncology.

CD20-Directed Antibody-Mediated Immunotherapy Induces Responses and Facilitates Hematologic Recovery in Patients With Waldenstrom's Macroglobulinemia.

J. Byrd, E. Kimby, D. Agus, 2001, Journal of immunotherapy : official journal of the Society for Biological Therapy.

Long-Term Follow-up of Reduced Intensity Allogeneic Stem Cell Transplantation for Chronic Lymphocytic Leukemia: Prognostic Model to Predict Outcome

J. Gribben, Catherine J. Wu, J. Ritz, 2012, Leukemia.

Vismodegib for advanced basal cell carcinoma: Duration of response after vismodegib discontinuation and response to vismodegib retreatment upon disease progression.

A. Hauschild, A. Gesierich, J. Hainsworth, 2014 .

Full facial edema: a novel presentation of subcutaneous panniculitis-like T-cell lymphoma.

D. Fisher, T. Kupper, G. Murphy, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Combination of Duvelisib, a PI3K-δ,γ Inhibitor, and Romidepsin Is Highly Active in Relapsed/Refractory Peripheral T-Cell Lymphoma with Low Rates of Transaminitis: Results of Parallel Multicenter, Phase 1 Combination Studies with Expansion Cohorts

D. Fisher, S. Horwitz, E. Jacobsen, 2018, Blood.

High-throughput sequencing of the T cell receptor β gene identifies aggressive early-stage mycosis fungoides

R. Clark, P. Devlin, H. Robins, 2018, Science Translational Medicine.

Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era

A. LaCasce, A. Freedman, P. Armand, 2013, British journal of haematology.

THE COMBINATION OF DUVELISIB AND ROMIDEPSIN (DR) IS HIGHLY ACTIVE AGAINST RELAPSED/REFRACTORY PERIPHERAL T‐CELL LYMPHOMA WITH LOW RATES OF TRANSAMINITIS: FINAL RESULTS

D. Fisher, S. Horwitz, E. Jacobsen, 2021, Hematological Oncology.

Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning.

A. LaCasce, A. Freedman, P. Armand, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome.

A. LaCasce, A. Freedman, P. Armand, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Safety and Immunogenicity of Modi fi ed Vaccinia Ankara in Hematopoietic Stem Cell Transplant Recipients : A Randomized , Controlled Trial

D. Fisher, M. Seaman, K. Verrill, 2013 .

Long-term results of a prospective trial of mantle irradiation alone for early-stage Hodgkin's disease.

D. Neuberg, A. Ng, B. Silver, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

A T Cell Inflammatory Phenotype is Associated with Autoimmune Toxicity of the PI3K Inhibitor Duvelisib in Chronic Lymphocytic Leukemia

Emily M. Thrash, S. Tyekucheva, S. Fernandes, 2021, Leukemia.

Initial Results of a Multicenter, Phase II Study of Ibrutinib Plus FCR (iFCR) As Frontline Therapy for Younger CLL Patients

M. Davids, D. Fisher, C. Jacobson, 2016 .

Initial Results of a Phase Ib Study of Ibrutinib in Combination with Obinutuzumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

A. LaCasce, M. Davids, D. Fisher, 2017 .

UPDATED RESULTS OF A MULTICENTER PHASE I/IB STUDY OF TGR‐1202 IN COMBINATION WITH IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY MCL OR CLL

M. Davids, D. Fisher, C. Jacobson, 2017 .

Pityriasis rubra pilaris‐like erythroderma secondary to phosphoinositide 3‐kinase inhibition

J. Brown, D. Fisher, N. LeBoeuf, 2018, Clinical and experimental dermatology.

Preliminary Results of a Phase Ib Study of Duvelisib in Combination with FCR (dFCR) in Previously Untreated, Younger Patients with CLL

M. Davids, D. Fisher, Jennifer R. Brown, 2015 .

A multicenter phase II study of venetoclax plus dose-adjusted R-EPOCH (VR-EPOCH) for Richter’s syndrome.

S. Tyekucheva, M. Davids, D. Fisher, 2020 .

Comparative Outcome of Myeloablative and Reduced Intensity Allogeneic Stem Cell Transplantation for Chronic Lymphocytic Leukemia.

J. Gribben, J. Ritz, K. Stevenson, 2008 .

A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia

E. D. Jacobsen, A. LaCasce, S. Tyekucheva, 2023, Leukemia.

Sequencing-Based Detection of Circulating Tumor DNA in the Autologous Stem Cell Grafts of Patients with Diffuse Large B-Cell Lymphoma Undergoing Hematopoietic Stem Cell Transplantation

A. LaCasce, J. Ritz, M. Faham, 2015 .

Updated Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab (AVO) for Frontline Treatment of Chronic Lymphocytic Leukemia (CLL)

A. LaCasce, S. Tyekucheva, P. Armand, 2020, Blood.

Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL).

A. LaCasce, S. Tyekucheva, P. Armand, 2019, Blood.

Study of Dasatinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

A. LaCasce, D. Neuberg, P. Armand, 2011 .

Cancer Therapy : Clinical Phase II Study of Dasatinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

A. LaCasce, D. Neuberg, P. Armand, 2011 .

Updated Results from a Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL/SLL or Richter's Syndrome

S. Tyekucheva, M. Davids, D. Fisher, 2020 .

TGR-1202 in Combination with Ibrutinib in Patients with Relapsed or Refractory CLL or MCL: Preliminary Results of a Multicenter Phase I/Ib Study

M. Davids, D. Fisher, C. Jacobson, 2016 .

Lenalidomide added to bendamustine-rituximab for untreated chronic lymphocytic leukemia (CLL): A phase 1 study.

D. Neuberg, P. Armand, M. Davids, 2015 .

Detection of circulating tumour DNA in patients with aggressive B‐cell non‐Hodgkin lymphoma

A. LaCasce, D. Neuberg, Y. Oki, 2013, British journal of haematology.

Characteristics and outcomes after autologous stem cell transplant for patients with relapsed or refractory diffuse large B-cell lymphoma who failed initial rituximab, cyclophosphamide, adriamycin, vincristine, and prednisone therapy compared to patients who failed cyclophosphamide, adriamycin, vinc

A. LaCasce, D. Neuberg, D. Fisher, 2010, Leukemia & lymphoma.

Recovery A fter S tem-Cell T ransplantation f or Hematologic D iseases

D. Fairclough, J. Weeks, D. Fisher, 2001 .

Small lymphocytic lymphoma presenting as chronic diffuse lip swelling.

D. Fisher, C. Larocca, M. Lorenzo, 2022, Dermatology online journal.

Unusual sites of Hodgkin's lymphoma: CASE 2. Hodgkin's lymphoma of the CNS masquerading as meningioma.

D. Fisher, Jennifer R. Brown, S. Tuli, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

B5, a new B cell-restricted activation antigen.

A. Freedman, D. Fisher, A. Boyd, 1985, Journal of immunology.

Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation.

W. Chan, D. Weisenburger, A. LaCasce, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation.

Matthew J. Frigault, A. LaCasce, M. Shipp, 2020, Blood advances.

Risk factors for development of pneumonitis after high-dose chemotherapy with cyclophosphamide, BCNU and etoposide followed by autologous stem cell transplant

A. LaCasce, D. Neuberg, A. Lane, 2012, Leukemia & lymphoma.

Safety of Mogamulizumab in Mycosis Fungoides and Sézary Syndrome: Final Results from the Phase 3 Mavoric Study

C. Elmets, R. Dummer, R. Cowan, 2019, Blood.

Imaging of Bing-Neel syndrome

S. Kesari, D. Fisher, M. Samuels, 2008, Neurology.

Anti-CCR4 Monoclonal Antibody, Mogamulizumab, Demonstrates Significant Improvement in PFS Compared to Vorinostat in Patients with Previously Treated Cutaneous T-Cell Lymphoma (CTCL): Results from the Phase III MAVORIC Study

C. Elmets, J. Scarisbrick, P. Zinzani, 2017 .

Response to brentuximab vedotin versus physician’s choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis

M. Weichenthal, R. Dummer, O. Akilov, 2021, European journal of cancer.

Sirolimus, Tacrolimus and Reduced-Dose Methotrexate as Graft Versus Host Disease (GVHD)Prophylaxis after Non-Myeloablative Stem Cell Transplantation: Low Incidence of Acute GVHD Compared with Tacrolimus/Methotrexate or Cyclosporine/Prednisone.

J. Gribben, J. Ritz, D. Fisher, 2004 .

Oral clofarabine for relapsed/refractory non-Hodgkin lymphomas: results of a phase 1 study

D. Neuberg, D. Fisher, E. Jacobsen, 2013, Leukemia & lymphoma.

Interim Positron Emission Tomography During Frontline Chemoimmunotherapy for Follicular Lymphoma

A. LaCasce, A. Zelenetz, M. Davids, 2023, HemaSphere.

Blood pressure is associated with occult cardiovascular disease in prospectively studied Hodgkin lymphoma survivors after chest radiation

K. Gauvreau, A. Ng, L. Diller, 2014, Leukemia & lymphoma.

INITIAL RESULTS OF A MULTICENTER PHASE 2 STUDY OF VENETOCLAX IN COMBINATION WITH DOSE‐ADJUSTED R‐EPOCH FOR PATIENTS WITH RICHTER'S SYNDROME (CRC‐043)

S. Tyekucheva, M. Davids, D. Fisher, 2019, Hematological Oncology.

Response to low-dose involved-field radiotherapy in patients with non-Hodgkin's lymphoma.

A. Ng, B. Silver, A. Freedman, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Panobinostat in combination with rituximab in heavily pretreated diffuse large B‐cell lymphoma: Results of a phase II study

D. Neuberg, D. Fisher, E. Jacobsen, 2018, Hematological oncology.

CpG Oligonucleotide (1018 ISS) May Overcome Rituximab (R) Resistance in Follicular Lymphoma (FL) through Enhanced ADCC, T Cell Expansion, and Alteration of Tumor Microenvironment.

J. Friedberg, R. Fisher, R. Coffman, 2005 .

A prospective study of minimal residual disease in patients with diffuse large B-cell lymphoma using an Ig-NGS assay

A. LaCasce, A. Freedman, P. Armand, 2020, Leukemia & lymphoma.

Mid- and post-ABVD gallium scanning predicts for recurrence in early-stage Hodgkin's disease.

A. D. Van den Abbeele, A. Ng, B. Silver, 2005, International journal of radiation oncology, biology, physics.

Revised Dose Ramp-Up to Mitigate the Risk of Tumor Lysis Syndrome When Initiating Venetoclax in Patients With Mantle Cell Lymphoma.

A. Roberts, M. Davids, D. Fisher, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Histopathologic spectrum of hypersensitivity reactions associated with anti‐CD52 therapy (alemtuzumab)

R. Clark, D. Fisher, T. Kupper, 2016, Journal of cutaneous pathology.

Updated Results from a Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Richter's Syndrome (RS)

A. Alencar, S. Tyekucheva, M. Davids, 2022, Blood.

Venetoclax plus Dose-Adjusted R-EPOCH (VR-EPOCH) for Richter's Syndrome.

S. Tyekucheva, Catherine J. Wu, M. Davids, 2021, Blood.

Isolation and functional analysis of human B cell populations. I. Characterization of the B1+B2+ and B1+B2- subsets.

D. Fisher, J. Groopman, A. Boyd, 1985, Journal of immunology.

Rituximab Added to CODOX-M/IVAC Is Highly Effective in HIV-Negative and hiv-Positive Burkitt Lymphoma

A. LaCasce, P. Armand, D. Fisher, 2008 .

Targeting constitutively active STAT3 in chronic lymphocytic leukemia: A clinical trial of the STAT3 inhibitor pyrimethamine with pharmacodynamic analyses

Zachary T. Giaccone, S. Tyekucheva, Catherine J. Wu, 2020, American journal of hematology.

Updated Results from a Phase II Study of Galiximab (Anti-CD80) in Combination with Rituximab for Relapsed or Refractory, Follicular NHL.

L. Gordon, M. Czuczman, J. Friedberg, 2005 .

Prognostic Value of Circulating Tumor DNA (ctDNA) in Autologous Stem Cell Graft and Post-Transplant Plasma Samples Among Patients with Diffuse Large B-Cell Lymphoma

A. LaCasce, A. Freedman, P. Armand, 2020, Blood.

Updated Analyses of the International, Open-Label, Randomized, Phase 3 Alcanza Study: Longer-Term Evidence for Superiority of Brentuximab Vedotin Versus Methotrexate or Bexarotene for CD30-Positive Cutaneous T-Cell Lymphoma (CTCL)

M. Weichenthal, R. Dummer, O. Akilov, 2017 .

Favorable outcomes following allogeneic transplantation in adults with hemophagocytic lymphohistiocytosis

A. LaCasce, S. Nikiforow, D. Fisher, 2022, Blood advances.

Imatinib mesylate lacks efficacy in relapsed/refractory peripheral T cell lymphoma

A. LaCasce, D. Neuberg, P. D. Dal Cin, 2015, Leukemia and Lymphoma.

Double Expressing (MYC/BCL2) and Double-Hit Diffuse Large B-Cell Lymphomas Have Inferior Survival Following Autologous Stem Cell Transplantation

D. Weisenburger, A. LaCasce, A. Nademanee, 2015 .

Unusual presentations of malignancy. Case 3. Mantle-cell lymphoma of soft tissue.

A. Thorner, D. Fisher, J. Hecht, 2001, Journal of Clinical Oncology.

An assessment of risk factors associated with ifosfamide-induced encephalopathy in a large academic cancer center

D. Neuberg, D. Fisher, Frank Cirrone, 2015, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Identification of An Active, Well-Tolerated Dose of Pralatrexate In Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma (CTCL): Final Results of a Multicenter Dose-Finding Study.

D. Fisher, S. Horwitz, N. Bartlett, 2010 .

Obatoclax in Combination with Fludarabine and Rituximab (FR) Is Well-Tolerated and Shows Promising Clinical Activity in Relapsed CLL/SLL

D. Neuberg, A. Freedman, D. Fisher, 2011 .

Reply to J. Mehta

A. LaCasce, A. Freedman, P. Armand, 2009 .

54: Inclusion of Sirolimus in the GVHD Prophylaxis Regimen is Associated with Improved Survival in Patients with Lymphoma Undergoing Allogeneic Transplantation

A. LaCasce, A. Freedman, P. Armand, 2008 .

Cyclophosphamide, doxorubicin, vincristine, prednisone dose intensification with granulocyte colony-stimulating factor markedly depletes stem cell reserve for autologous bone marrow transplantation.

J. Gribben, D. Neuberg, J. Ritz, 1997, Blood.

Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation

E. D. Jacobsen, A. LaCasce, M. Shipp, 2022, Blood advances.